Stampidine as a novel nucleoside reverse transcriptase inhibitor with potent anti-HIV activity

Arzneimittel-Forschung/Drug Research

Volumn 56, Issue 2 A, 2006, Pages 121-135

  Uckun, Fatih M ^a,b,c  

^a PARKER HUGHES INSTITUTE   (United States)

^b Paradigm Pharmaceuticals   (United States)

^c Ikaros Enterprises   (United States)

Author keywords

Anti HIV agents; Antiretroviral therapy; CAS 217178 62 6; CAS 3056 17 5; DDE 113; HI 113; N p (4 Bromophenyl) 2',3' didehydro 3' deoxy 5' thymidylyl L alanine methyl ester; Stampidine, clinical trials, pharmacology; Stavudine

Indexed keywords

AMPRENAVIR; CAS 217178 62 6; CAS 30516 87 1; CAS 3056 17 5; DDE 113; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HI 113; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAMPIDINE; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER TOXICITY; NEPHROLITHIASIS; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; RASH; REVIEW; VIRUS MUTATION;

EID: 33645114688     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296800     Document Type: Review

References (111)

1. Chaisson, R., HIV becomes world's leading infectious cause of death. The Hopkins HIV Report, July 1999. http://www.aegis. com/pubs/jhopkins/1999/ JH990702.html, accessed June 1, 2005
2. Worldwide HIV & AIDS Epidemic Statistics, http://www. avert.org/worlstatinfo.htm, accessed June 1, 2005
3. Palella, F. J., Jr., Delaney, K. M., Moorman, A. C. et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338, 853 (1998)
4. Smit, C., Geskus, R., Uitenbroek, D. et al., Declining AIDS mortality in Amsterdam: contributions of declining HIV incidence and effective therapy. Epidemiology 15, 536 (2004)
5. Bogaards, J. A., Goudsmit, J., Meeting the immense need for HAART in resource-poor settings. J. Antimicrob. Chemother. 52, 743 (2003)
6. Moatti, J. P., N'Doye, I., Hammer, S. M. et al., Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm. Nat. Med. 9, 1449 (2003)
7. Craigo, J. K., Patterson, B. K., Paranjpe, S. et al., Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. AIDS Res. Hum. Retroviruses 20, 1196 (2004)
8. HIV and AIDS statistics and features, end of 2002 and 2004. North America, Western and Central Europe, http://www. unaids.org/wad2004/ EPIupdate2004_html_en/Epi04_12_en. htm, accessed June 1, 2005.
9. De Clercq, E., Antiviral drugs in current clinical use. J. Clin. Virol. 30, 115 (2004)
10. Gulick, R. M., New antiretroviral drugs. Clin. Microbiol. Infect. 9, 186 (2003)
11. Browne, M. J., Mayer, K. H., Chafee, S. B. et al., 2',3'-didehydro-3'- deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J. Infect. Dis. 167, 21 (1993)
12. Murray, H. W., Squires, K. E., Weiss, W. et al., Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. J. Infect. Dis. 171 (Suppl. 2), S123 (1995)
13. Petersen, E. A., Ramirez-Ronda, C. H., Hardy, W. D. et al., Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J. Infect. Dis. 171 (Suppl. 2), S131 (1995)
14. Griffith, B. P., Brett-Smith, H., Kim, G. et al., Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J. Infect. Dis. 173, 1252 (1996)
15. Katlama, C., Valantin, M. A., Matheron, S. et al., Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection. Ann. Intern. Med. 129, 525 (1998)
16. Richman, D. D., Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus. Am. J. Med. 88, 8S (1990)
17. Riddler, S. A., Anderson, R. E., Mellors, J. W., Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T). Antiviral Res. 27, 189 (1995)
18. Skowron, G., Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J. Infect. Dis. 171 (Suppl. 2), S113 (1995)
19. Balzarini, J., Herdewijn, P., De Clercq, E., Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 264, 6127 (1989)
20. Baba, M., Pauwels, R., Herdewijn, E et al., Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem. Biophys. Res. Commun. 142, 128 (1987)
21. Ho, H. T., Hitchcock, M. J., Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob. Agents Chemother. 33, 844 (1989)
22. Mansuri, M. M., Starrett, J. E., Jr., Ghazzouli, I. et al., 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent. J. Med. Chem. 32, 461 (1989)
23. Zhu, Z., Ho, H. T., Hitchcock, M. J. et al., Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells. Biochem. Pharmacol. 39, R15 (1990)
24. Sommadossi, J. P., Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2',3'-dideoxynucleoside analogues. J. Infect. Dis. 171 (Suppl. 2), S88 (1995)
25. Dudley, M. N., Graham, K. K., Kaul, S. et al., Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J. Infect. Dis. 166, 480 (1992)
26. Horton, C. M., Dudley, M. N., Kaul, S. et al., Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob. Agents Chemother. 39, 2309 (1995)
27. Kaul, S., Dandekar, K. A., Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys. Antimicrob. Agents Chemother. 37, 1160 (1993)
28. 4[28] Rana, K. Z., Dudley, M. N., Clinical pharmacokinetics of stavudine. Clin. Pharmacokinet. 33, 276 (1997)
29. Martin, J. C., Hitchcock, M. J., Fridland, A. et al., Comparative studies of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) with other pyrimidine nucleoside analogues. Ann. N. Y. Acad. Sci. 616, 22 (1990)
30. Lea, A. P., Faulds, D., Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 51, 846 (1996)
31. Chappuy, H., Treluyer, J. M., Jullien, V. et al., Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. 48, 4332 (2004)
32. Rongkavilit, C., Thaithumyanon, P., Chuenyam, T. et al., Pharmacokinetics of stavudine and didanosine coadministered with nelfmavir in human immunodeficiency virus-exposed neonates. Antimicrob. Agents Chemother. 45, 3585 (2001)
33. Wade, N. A., Unadkat, J. D., Huang, S. et al., Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J. Infect. Dis. 190, 2167 (2004)
34. Spruance, S. L., Pavia, A. T., Mellors, I. W. et al., Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann. Intern. Med. 126, 355 (1997)
35. Merrill, D. P., Moonis, M., Chou, T. C. et al., Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J. Infect. Dis. 173, 355 (1996)
36. Eron, J. J., Benoit, S. L., Jemsek, J. et al., Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N. Engl. J. Med. 333, 1662 (1995)
37. Bartlett, J. A., Benoit, S. L., Johnson, V. A. et al., Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Ann. Intern. Med. 125, 161 (1996)
38. Gulick, R. M., Mellors, J. W., Havlir, D. et al., 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann. Intern. Med. 133, 35 (2000)
39. Rouleau, D., Conway, B., Raboud, J. et al., Stavudine plus lamivudine in advanced human immunodeficiency virus disease: a short-term pilot study. J. Infect. Dis. 176, 1156 (1997)
40. Kuritzkes, D. R., Marschner, I., Johnson, V. A. et al., Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. Aids 13, 685 (1999)
41. Raffi, E, Reliquet, V., Auger, S. et al., Efficacy and safely of stavudine and didanosine combination therapy in antiretroviral-experienced patients. Aids 12, 1999 (1998)
42. Eron, J. J., Jr., Murphy, R. L., Peterson, D. et al., A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). Aids 14, 1601 (2000)
43. Squires, K. E., Gulick, R., Tebas, P. et al., A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). Aids 14, 1591 (2000)
44. Katlama, C., Pellegrin, J. L., Lacoste, D. et al., MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine. HIV Med. 2, 20 (2001)
45. Joly, V., Flandre, P., Meiffredy, V. et al., Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial). Antimicrob. Agents Chemother. 46, 1906 (2002)
46. Gallant, J. E., Chaisson, R. E., Keruly, J. C. et al., Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients. Aids 13, 225 (1999)
47. Calvez, V., Costagliola, D., Descamps, D. et al., Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antivir. Ther. 7, 211 (2002)
48. Havlir, D. V., Tierney, C., Friedland, G. H. et al., In vivo antagonism with zidovudine plus stavudine combination therapy. J. Infect. Dis. 182, 321 (2000)
49. Hoggard, P. G., Sales, S. D., Phiboonbanakit, D. et al., Influence of prior exposure to zidovudine on stavudine phos-phorylation in vivo and ex vivo. Antimicrob. Agents Chemother. 45, 577 (2001)
50. Ahluwalia, G. S., Gao, W. Y., Mitsuya, H. et al., 2',3'-Didehydro-3'- deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5'-triphosphate biosynthesis. Mol. Pharmacol. 50, 160 (1996)
51. Launay, O., Gerard, L., Morand-Joubert, L. et al., Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1. Clin. Infect. Dis. 35, 1096 (2002)
52. Carpenter, C. C., Cooper, D. A., Fischl, M. A. et al., Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. J. Am. Med. Assoc. 283, 381 (2000)
53. Delfraissy, J. F., New French guidelines for antiretroviral treatment. HIV Med. 1, 133 (2000)
54. Van Leeuwen, R., Katlama, C., Murphy, R. L. et al., A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. Aids 17, 987 (2003)
55. Gallant, J. E., Staszewski, S., Pozniak, A. L. et al., Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. J. Am. Med. Assoc. 292, 191 (2004)
56. Saag, M. S., Cahn, P., Raffi, F. et al., Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. J. Am. Med. Assoc. 292, 180 (2004)
57. Van Leth, F., Phanuphak, P., Ruxrungtham, K. et al., Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363, 1253 (2004)
58. Gulick, R. M., Smeaton, L. M., D'Aquila, R. T. et al., Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. J. Infect. Dis. 183, 715 (2001)
59. Becher, F., Pruvost, A. G., Schlemmer, D. D. et al., Significant levels of intracellular stavudine triphosphate are found in HIV-infected zidovudine-treated patients. Aids 17, 555 (2003)
60. Cossarizza, A., Moyle, G., Antiretroviral nucleoside and nucleotide analogues and mitochondria. Aids 18, 137 (2004)
61. Fleischer, R., Boxwell, D., Sherman, K. E., Nucleoside analogues and mitochondrial toxicity. Clin. Infect. Dis. 38, e79 (2004)
62. Lee, H., Hanes, J., Johnson, K. A., Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42, 14711 (2003)
63. Dalakas, M. C., Peripheral neuropathy and antiretroviral drugs. J. Peripher. Nerv. Syst. 6, 14 (2001)
64. Joly, V., Flandre, P., Meiffredy, V. et al., Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. Aids 16, 2447 (2002)
65. Boubaker, K., Flepp, M., Sudre, P. et al., Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin. Infect. Dis. 33, 1931 (2001)
66. Birkus, G., Hitchcock, M. J., Cihlar, T., Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46, 716 (2002)
67. Martin, J. L., Brown, C. E., Matthews-Davis, N. et al., Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38, 2743 (1994)
68. Sluis-Cremer, N., Arion, D., Parniak, M. A., Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell. Mol. Life Sci. 57, 1408 (2000)
69. Lacey, S. F., Larder, B. A., Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture. Antimicrob. Agents Chemother. 38, 1428 (1994)
70. Gu, Z., Gao, Q., Fang, H. et al., Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. Leukemia 8 (Suppl. 1), S166 (1994)
71. Ross, L., Johnson, M., Graham, N. et al., The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy. J. Hum. Virol. 2, 290 (1999)
72. Whitcomb, J. M., Parkin, N. T., Chappey, C. et al., Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J. Infect. Dis. 188, 992 (2003)
73. Lin, P. F., Samanta, H., Rose, R. E. et al., Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J. Infect. Dis. 170, 1157 (1994)
74. Lennerstrand, J., Stammers, D. K., Larder, B. A., Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob. Agents Chemother. 45, 2144 (2001)
75. Pellegrin, I., Izopet, J., Reynes, J. et al., Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group. Aids 13, 1705 (1999)
76. Reynes, J., Denisi, R., Massip, P. et al., Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group. J. Acquir. Immune Defic. Syndr. 22, 103 (1999)
77. Mouroux, M., Izopet, J., Descamps, D. et al., Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T. Pathol. Biol. (Paris) 48, 508 (2000)
78. Mouroux, M., Descamps, D., Izopet, J. et al., Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy. Antivir. Ther. 6, 179 (2001)
79. Shulman, N., Shafer, R., Winters, R., et al. ACTG 302, 8th Conference on Retroviral Opportunistic Infections. Chicago, IL, USA, February 4-8, 2001. Abstract 437
80. Izopet, J., Bicart-See, A., Pasquier, C. et al., Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J. Med. Virol. 59, 507 (1999)
81. Duan, C., Poticha, D., Stoeckli, T., et al. 8th Conference on Retroviral Opportunistic Infections. Chicago, IL, USA, February 4-8, 2001. Abstract 442
82. McGuigan, C., Tsang, H. W., Sutton, P. W. et al., Synthesis and anti-HIV activity of some novel chain-extended phosphoramidate derivatives of d4T (stavudine): esterase hydrolysis as a rapid predictive test for antiviral potency. Antivir. Chem. Chemother. 9, 109 (1998)
83. McGuigan, C., Cahard, D., Sheeka, H. M. et al., Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. J. Med. Chem. 39, 1748 (1996)
84. Vig, R., Venkatachalam, T. K., Uckun, F. M., D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] as a potent and non-toxic anti-human immunodeficiency virus agent. Antivir. Chem. Chemother. 9, 445 (1998)
85. Venkatachalam, T. K., Tai, H. L., Vig, R. et al., Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives. Bioorg. Med. Chem. Lett. 8, 3121 (1998)
86. Uckun, F. M., Pendergrass, S., Qazi, S. et al., Phenyl phosphoramidate derivatives of stavudine as anti-HIV agents with potent and selective in-vitro antiviral activity against adenovirus. Eur. J. Med. Chem. 39, 225 (2004)
87. Uckun, F. M., Samuel, P., Qazi, S. et al., Effects of aryl substituents on the anti-HIV activity of the arylphosphoramidate derivatives of stavudine. Antivir. Chem. Chemother. 13, 197 (2002)
88. Uckun, F. M., Pendergrass, S., Venkatachalam, T. K. et al., Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations. Antimicrob. Agents Chemother. 46, 3613 (2002)
89. Uckun, F. M., Pendergrass, S., Qazi, S. et al., In vitro activity of Stampidine against primary clinical human immunodeficiency virus isolates. Arzneimittel-Forschung/ Drug Res. 54, 69 (2004)
90. Uckun, F. M., Qazi, S., Pendergrass, S. et al., In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (Stampidine) in mice. Antimicrob. Agents Chemother. 46, 3428 (2002)
91. Uckun, F. M., Chen, C. L., Samuel, P. et al., In vivo antiretroviral activity of Stampidine in chronically feline immunodeficiency virus-infected cats. Antimicrob. Agents Chemother. 47, 1233 (2003)
92. Uckun, F. M., Chen, C. L., Lisowski, E. et al., Toxicity and pharmacokinetics of Stampidine in mice and rats. Arzneim.-Forsch./Drug Res. 53, 357 (2003)
93. Chen, C. L., Yu, G., Venkatachalam, T. K. et al., Metabolism of stavudine-5'-[p-bromophenyl methoxyalaninyl phosphate], stampidine, in mice, dogs, and cats. Drug Metab. Dispos. 30, 1523 (2002)
94. Venkatachalam, T. K., Samuel, P., Li, G. et al., Lipase-mediated stereoselective hydrolysis of stampidine and other phosphoramidate derivatives of stavudine. Bioorg. Med. Chem. 12, 3371 (2004)
95. Venkatachalam, T. K., Yu, G., Samuel, P. et al., A comparative study of the hydrolysis pathways of substituted aryl phosphoramidate versus aryl thiophosphoramidate derivatives of stavudine. Eur. J. Med. Chem. 39, 665 (2004)
96. Venkatachalam, T. K., Samuel, P., Uckun, F. M., Stereo-chemical influence on lipase-mediated hydrolysis and biological activity of stampidine and other stavudine phosphoramidates. Bioorg. Med. Chem. 13, 1763 (2005)
97. Qazi, S., Samuel, N. K., Venkatachalam, T. K. et al., Evaluating dissolution profiles of an anti-HIV agent using ANOVA and non-linear regression models in JMP software. Int. J. Pharm. 252, 27 (2003)
98. D'Cruz, O. J., Uckun, F. M., Stampidine is a potential nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. Fertil. Steril. 81 (Suppl. 1), 831 (2004)
99. D'Cruz, O., Samuel, P., Waurzyniak, B. et al., In vivo evaluation of a gel formulation of stampidine, a novel non-spermicidal broad-spectrum anti-human immunodeficiency virus microbicide. Am. J. Drug Deliv. 1, 275 (2003)
100. D'Cruz, O., Samuel, P., Uckun, E, Conceival, a Novel Noncontraceptive Vaginal Vehicle for Lipophilic Microbicides. AAPS Pharm. Sci. Tech. 6, E56 (2005)
101. D'Cruz, O. J., Uckun, F. M., Stampidine: a selective oculo-genital microbicide. J. Antimicrob. Chemother. 56, 10 (2005)
102. Uckun, F. M., Qazi, S., Venkatachalam, T. K., In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs. Arzneim.-Forsch./Drug Res. 55, 223 (2005)
103. United States Patent No. 6030957. Issued: 2/29/00. Aryl phosphate derivatives of d4T having anti-HIV activity. Uckun, F. M., Vig, R.
104. United States Patent No. 6350736. Issued: 2/26/02. Aryl phosphate derivatives of d4T having anti-HIV activity. Uckun, F. M., Vig, R.
105. United States Patent No. 6465641. Issued: 10/15/02. One pot synthesis of 5'-hydroxy phosphorylated nucleoside derivatives, and compounds formed thereby. Uckun, F. M., Jan, S.-T.
106. United States Patent No. 6503890. Issued: 1/7/03. Aryl phosphate derivatives of d4T having anti-HIV activity. Uckun, F. M.
107. United States Patent No. 6528495. Issued: 3/4/03. Aryl phosphate derivatives of d4T having anti-HIV activity. Uckun, F. M., Vig, R.
108. United States Patent No. 6537975. Issued: 3/25/03. Aryl phosphate derivatives of d4T having anti-HIV activity. Uckun, F. M., Vig, R.
109. United States Patent No. 6670336. Issued: 12/30/03. Aryl phosphate derivatives of d4T having anti-HIV activity. Uckun, F. M., Vig, R.
110. Venkatachalam, T. K., et al., United States Patent No. 6825177. Issued: 11/30/04. Aryl phosphate derivatives of D4T with potent anti-viral activity. Uckun, F. M., Chen, C.-L.
111. European Patent No. EP 1 090 018 B1. Issued: 9/29/ 04. Aryl Phosphate Derivatives of d4T Having Anti-HIV Activity. Uckun, F. M., Vig, R.